Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma.
暂无分享,去创建一个
Angray S. Kang | R. Xiang | R. Reisfeld | N. Varki | H. Lode | T. Dreier
[1] S. Gillies,et al. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. , 1997, Journal of the National Cancer Institute.
[2] S. Gillies,et al. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. , 1997, Cancer research.
[3] L. Zitvogel,et al. Cytokine Gene Therapy of Cancer Using Interleukin‐12: Murine and Clinical Trials , 1996, Annals of the New York Academy of Sciences.
[4] N. Yang,et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[5] J. Becker,et al. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy , 1996, The Journal of experimental medicine.
[6] L. Zitvogel,et al. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. , 1995, Journal of immunology.
[7] L. Zitvogel,et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. , 1995, Journal of immunology.
[8] SCIENCESCOPE , 1995, Science.
[9] D. Carvajal,et al. Mouse interleukin‐12 (IL‐12) p40 homodimer: a potent IL‐12 antagonist , 1995, European journal of immunology.
[10] G. Trinchieri,et al. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. , 1994, Blood.
[11] E. Jaffee,et al. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. , 1993, Cancer research.
[12] Susanne A. Fischer,et al. The interleukin‐12 subunit p40 specifically inhibits effects of the interleukin‐12 heterodimer , 1993, European journal of immunology.
[13] F. Podlaski,et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[14] G. Trinchieri,et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes , 1989, Journal of Experimental Medicine.
[15] R. Bruccoleri,et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[16] W. Shain,et al. Neuronal properties of hybrid neuroblastoma X sympathetic ganglion cells. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[17] R. Mulligan,et al. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo , 1997, Nature Biotechnology.
[18] Simon C Watkins,et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. , 1994, Cancer research.